Amarin Corp plc (AMRN) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Amarin (AMRN): Goldman Remains Neutral as Investors Await FDA Response on ANCHOR Appeal
August 8, 2014 1:05 PM EDTGoldman Sachs maintained a Neutral rating on Amarin Corporation (NASDAQ: AMRN) with a price target of $1.90. Comments follow Q2 results. Analyst Gary Nachman said he was awaiting FDA response on its ANCHOR appeal.
"The Vascepa co-promote with Kowa began in mid-May and we have started to see a positive impact on Rxs, but it is... More
Amarin Corp plc (AMRN) Files $300M Mixed Securities Shelf
August 7, 2014 4:22 PM EDTAmarin Corp plc (NASDAQ: AMRN) filed a $300 million mixed securities shelf on form S-3.
... More